Research programme: thrombolytic therapy - Synthon

Drug Profile

Research programme: thrombolytic therapy - Synthon

Alternative Names: BLX-155

Latest Information Update: 10 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biolex
  • Developer Synthon
  • Class Serine endopeptidases
  • Mechanism of Action Fibrinolysis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute coronary syndromes; Deep vein thrombosis; Peripheral arterial occlusive disorders

Most Recent Events

  • 07 May 2012 Preclinical development is ongoing in USA
  • 07 May 2012 Synthon acquires BLX 155 from Biolex Therapeutics
  • 16 Jul 2009 Pharmacodynamics data from a preclinical trial in Peripheral arterial occlusive disorders presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top